Teva Pharmaceutical Industries, Ltd.: Multiple Sclerosis, Relapsing-Remitting trials

The registry lists 14 Multiple Sclerosis, Relapsing-Remitting studies with Teva Pharmaceutical Industries, Ltd. as lead sponsor. 0 are open to participants now and 9 have results posted.

Phase 2 3Phase 3 7Phase 4 3No phase 1(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Safety and Tolerability of Glatiramer AcetateCompletedNCT01874145Phase 3Results posted
• An Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)TerminatedNCT01578785Phase 3Results posted
• Evaluation of Two Glatiramer Acetate (GA) Formulations in Relapsing-Remitting Multiple Sclerosis (RRMS) PatientsCompletedNCT01167426Phase 3Results posted
• A Study in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS) to Assess the Efficacy, Safety and Tolerability of Glatiramer Acetate (GA) Injection 40 mg Administered Three Times a Week Compared to PlaceboCompletedNCT01067521Phase 3Results posted
• Safety of New Formulation of Glatiramer AcetateCompletedNCT00947752Phase 3Results posted
• An Extension Study of LAQ/5062 Exploring the Long Term Safety, Tolerability and Clinical Effect Parameters During the DiseaseTerminatedNCT00745615Phase 2Results posted
• Clinical Trial Comparing Treatment of Relapsing-Remitting Multiple Sclerosis (RR-MS) With Two Doses of Glatiramer Acetate (GA).CompletedNCT00337779Phase 3Results posted
• Assessment Study of Steroid Effect in Relapsing Multiple Sclerosis Subjects Treated With Glatiramer AcetateTerminatedNCT00203047Phase 4Results posted
• Glatiramer Acetate (Copaxone®) Study to Follow Participants From the First Original Study for Safety and EffectivenessCompletedNCT00203021Phase 4Results posted
• A Study to Evaluate 2 Doses Of Oral Administration Of Laquinimod Compared to Interferon ß-1a Administered by Injection in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)WithdrawnNCT01975298Phase 3
• A Study to Evaluate the Effectiveness, Tolerability and Safety of LaquinimodCompletedNCT00349193Phase 2
• A Study to Evaluate the Long Term Safety and Effectiveness of Novantrone Therapy Followed by Copaxone Treatment for Multiple SclerosisCompletedNCT00203086
• A Study to Evaluate the Safety and Effectiveness of Novantrone Therapy Followed by Copaxone for Multiple Sclerosis.CompletedNCT00203073Phase 2
• Randomized Study Designed to Look at Disease Progression Using 2 Currently FDA Approved Drugs for the Treatment of RRMSTerminatedNCT00202995Phase 4